Epilepsy
Added to TX CUP: 2015
What We Know About Epilepsy in the CUP Context
Epilepsy is the original Texas CUP qualifying condition — SB 339 in 2015 specifically authorized low-THC cannabis for intractable epilepsy. The intractable framing was deliberate: the program targeted patients who had failed multiple anti-seizure medications, not first-line epilepsy generally.
Epilepsy encompasses many syndromes with very different prognoses — Dravet syndrome, Lennox-Gastaut syndrome, focal epilepsies, idiopathic generalized epilepsies, and others. CUP evaluation considerations vary by syndrome and by treatment history.
How TX CUP Addresses Epilepsy
Low-THC products under the CUP for epilepsy patients are CBD-dominant in practice; the low-THC cap aligns with the cannabinoid profile most studied for seizure indications. FDA-approved Epidiolex is a separate pharmaceutical — not a TX CUP product — and should not be conflated.
Our Experience Treating Epilepsy Patients Under CUP
Considerations CURT physicians evaluating epilepsy patients typically address:
- Coordination with the patient’s neurologist or epileptologist
- Documentation of prior anti-seizure medication trials and outcomes
- Seizure diary review for baseline frequency and pattern
- Drug-interaction screening (cannabinoid-AED interactions are clinically significant)
- Pediatric considerations — caregiver capacity for dosing precision and titration
What to Expect at the Evaluation
A CURT physician evaluating an epilepsy patient typically reviews:
- Neurology consult notes establishing diagnosis and syndrome classification where applicable
- EEG and MRI results
- Complete medication history with doses, durations, and reasons for discontinuation
- Current seizure frequency
- Treatment-related side effects from current and prior regimens
Pediatric evaluations require parent or legal guardian presence and may involve additional intake steps.
Common Patient Questions About Epilepsy and the TX CUP
Last Verified
Next Step
Bookings route through miracleleaftx.com.